Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case report

Gynecol Oncol. 2004 Jan;92(1):365-7. doi: 10.1016/j.ygyno.2003.09.004.

Abstract

Background: We are reporting on a case of platinum-refractory low-grade ovarian cancer responding to treatment with an allogeneic bone marrow transplantation from an unrelated donor.

Case: The 37-year-old patient received a preparative regimen consisting of fludarabine 25 mg/m(2) on days -6, -5, -4, -3 and -2, melphalan 70 mg/m(2) on days -3 and -2, and thymoglobulin 2 mg/kg on days -3, -2 and -1. An unrelated HLA-compatible bone marrow was infused on day 0. Graft-versus-host disease prophylaxis consisted of tacrolimus and methotrexate. The patient demonstrated complete donor chimerism. Serial CT scans of the abdomen and pelvis over the following 15 months showed a slow regression of the malignant lesion.

Conclusion: Engraftment of an unrelated donor marrow was achieved in a patient with ovarian cancer and induced a tumor response. This suggests the presence of a graft-versus-tumor effect in ovarian cancer. Further study is underway.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antilymphocyte Serum / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow Transplantation*
  • Drug Resistance, Neoplasm
  • Female
  • Graft vs Tumor Effect*
  • Humans
  • Melphalan / administration & dosage
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / immunology
  • Ovarian Neoplasms / surgery*
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives*

Substances

  • Antilymphocyte Serum
  • Vidarabine
  • fludarabine
  • Melphalan